Associations between fibrocytes and postcontrast myocardial T1 times in hypertrophic cardiomyopathy

Journal of the American Heart Association

Volumn 2, Issue 5, 2013, Pages

  Fang, Lu ^a   Beale, Anna ^a   Ellims, Andris H ^a,b   Moore, Xiao Lei ^a   Ling, Liang Han ^a,b   Taylor, Andrew J ^a,b   Chin Dusting, Jaye ^a   Dart, Anthony M ^a,b,c  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Fibroblasts; Hypertrophic cardiomyopathy; Myocardial fibrosis; T1 mapping

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CD34 ANTIGEN; CD45 ANTIGEN; CHEMOKINE; COLLAGEN TYPE 1; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GADOLINIUM PENTETATE MEGLUMINE; MATRIX PROTEIN; STROMAL CELL DERIVED FACTOR 1;

ADULT; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CD34+ FIBROCYTE; CD45+ FIBROCYTE; CELL DIFFERENTIATION; CELL TRANSPORT; CHEMOKINE BLOOD LEVEL; CLINICAL ARTICLE; COLLAGEN I+ FIBROCYTE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOKINE BLOOD LEVEL; DISEASE CLASSIFICATION; FEMALE; FIBROCYTE; FLOW CYTOMETRY; GENE EXPRESSION; HEART MUSCLE FIBROSIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HYPERTROPHIC CARDIOMYOPATHY; MALE; MESENCHYMAL STEM CELL; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE SCANNER; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; STROMAL CELL DERIVED FACTOR 1 BLOOD LEVEL; CELL CULTURE; CYTOLOGY; FIBROBLAST; FIBROSIS; HEART MUSCLE; MIDDLE AGED; MONONUCLEAR CELL; PATHOLOGY; T1 MAPPING;

FIBROBLASTS; HYPERTROPHIC CARDIOMYOPATHY; MYOCARDIAL FIBROSIS; T1 MAPPING;

CARDIOMYOPATHY, HYPERTROPHIC; CELL DIFFERENTIATION; CELLS, CULTURED; FEMALE; FIBROSIS; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MYOCARDIUM;

EID: 84891674102     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.113.000270     Document Type: Article

References (37)

1. Dobaczewski M, Frangogiannis NG. Chemokines and cardiac fibrosis. Front Biosci (Schol Ed). 2009;1:391-405.
2. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation. 2002;105:1503-1508.
3. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002; 287:1308-1320.
4. Varnava AM, Elliott PM, Sharma S, McKenna WJ, Davies MJ. Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart. 2000;84:476-482.
5. Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol. 2000;35:36-44.
6. Mewton N, Liu CY, Croisille P, Bluemke D, Lima JA. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol. 2011;57: 891-903.
7. Kim RJ, Judd RM. Gadolinium-enhanced magnetic resonance imaging in hypertrophic cardiomyopathy: in vivo imaging of the pathologic substrate for premature cardiac death? J Am Coll Cardiol. 2003;41:1568-1572.
8. Teraoka K, Hirano M, Ookubo H, Sasaki K, Katsuyama H, Amino M, Abe Y, Yamashina A. Delayed contrast enhancement of MRI in hypertrophic cardiomyopathy. Magn Reson Imaging. 2004;22:155-161.
9. Iles L, Pfluger H, Phrommintikul A, Cherayath J, Aksit P, Gupta SN, Kaye DM, Taylor AJ. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol. 2008; 52:1574-1580.
10. Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, McGregor C, Moon JC. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation. 2010;122:138-144.
11. Sibley CT, Noureldin RA, Gai N, Nacif MS, Liu S, Turkbey EB, Mudd JO, van der Geest RJ, Lima JA, Halushka MK, Bluemke DA. T1 mapping in cardiomyopathy at cardiac MR: comparison with endomyocardial biopsy. Radiology. 2012;265: 724-732.
12. Chan W, Duffy SJ, White DA, Gao XM, Du XJ, Ellims AH, Dart AM, Taylor AJ. Acute left ventricular remodeling following myocardial infarction: coupling of regional healing with remote extracellular matrix expansion. JACC Cardiovasc Imaging. 2012;5:884-893.
13. Ng AC, Auger D, Delgado V, van Elderen SG, Bertini M, Siebelink HM, van der Geest RJ, Bonetti C, van der Velde ET, de Roos A, Smit JW, Leung DY, Bax JJ, Lamb HJ. Association between diffuse myocardial fibrosis by cardiac magnetic resonance contrast-enhanced T mapping and subclinical myocardial dysfunction in diabetic patients: a pilot study. Circ Cardiovasc Imaging. 2012;5:51-59.
14. Ling LH, Kistler PM, Ellims AH, Iles LM, Lee G, Hughes GL, Kalman JM, Kaye DM, Taylor AJ. Diffuse ventricular fibrosis in atrial fibrillation: noninvasive evaluation and relationships with aging and systolic dysfunction. J Am Coll Cardiol. 2012;60:2402-2408.
15. Ellims AH, Iles LM, Ling LH, Hare JL, Kaye DM, Taylor AJ. Diffuse myocardial fibrosis in hypertrophic cardiomyopathy can be identified by cardiovascular magnetic resonance, and is associated with left ventricular diastolic dysfunction. J Cardiovasc Magn Reson. 2012;14:76.
16. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, Chandraker A, Yuan X, Pu WT, Roberts AB, Neilson EG, Sayegh MH, Izumo S, Kalluri R. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med. 2007;13:952-961.
17. Bucala R, Spiegel LA, Chesney J, Hogan M, Cerami A. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med. 1994;1:71-81.
18. Abe R, Donnelly SC, Peng T, Bucala R, Metz CN. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol. 2001; 166:7556-7562.
19. Bellini A, Mattoli S. The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab Invest. 2007;87:858-870.
20. Keeley EC, Mehrad B, Strieter RM. The role of fibrocytes in fibrotic diseases of the lungs and heart. Fibrogenesis Tissue Repair. 2011;4:2.
21. Keeley EC, Mehrad B, Strieter RM. The role of circulating mesenchymal progenitor cells (fibrocytes) in the pathogenesis of fibrotic disorders. Thromb Haemost. 2009;101:613-618.
22. Kisseleva T, Uchinami H, Feirt N, Quintana-Bustamante O, Segovia JC, Schwabe RF, Brenner DA. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J Hepatol. 2006;45:429-438.
23. Moeller A, Gilpin SE, Ask K, Cox G, Cook D, Gauldie J, Margetts PJ, Farkas L, Dobranowski J, Boylan C, O'Byrne PM, Strieter RM, Kolb M. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;179:588-594.
24. Sakai N, Wada T, Yokoyama H, Lipp M, Ueha S, Matsushima K, Kaneko S. Secondary lymphoid tissue chemokine (SLC/CCL21)/CCR7 signaling regulates fibrocytes in renal fibrosis. Proc Natl Acad Sci USA. 2006;103:14098-14103.
25. Chu PY, Mariani J, Finch S, McMullen JR, Sadoshima J, Marshall T, Kaye DM. Bone marrow-derived cells contribute to fibrosis in the chronically failing heart. Am J Pathol. 2010;176:1735-1742.
26. Sopel MJ, Rosin NL, Lee TD, Legare JF. Myocardial fibrosis in response to angiotensin II is preceded by the recruitment of mesenchymal progenitor cells. Lab Invest. 2011;91:565-578.
27. Gai N, Turkbey EB, Nazarian S, van der Geest RJ, Liu CY, Lima JA, Bluemke DA. T1 mapping of the gadolinium-enhanced myocardium: adjustment for factors affecting interpatient comparison. Magn Reson Med. 2011;65: 1407-1415.
28. Fang L, Moore XL, Chan W, White DA, Chin-Dusting J, Dart AM. Decreased fibrocyte number is associated with atherosclerotic plaque instability in man. Cardiovasc Res. 2012;95:124-133.
29. Quan TE, Bucala R. Culture and analysis of circulating fibrocytes. Methods Mol Med. 2007;135:423-434.
30. Shao DD, Suresh R, Vakil V, Gomer RH, Pilling D. Pivotal advance: Th-1 cytokines inhibit, and Th-2 cytokines promote fibrocyte differentiation. J Leukoc Biol. 2008;83:1323-1333.
31. Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY, Belperio JA, Keane MP, Strieter RM. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest. 2004;114: 438-446.
32. Mathai SK, Gulati M, Peng X, Russell TR, Shaw AC, Rubinowitz AN, Murray LA, Siner JM, Antin-Ozerkis DE, Montgomery RR, Reilkoff RA, Bucala RJ, Herzog EL. Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Lab Invest. 2010;90: 812-823.
33. Wang CH, Huang CD, Lin HC, Lee KY, Lin SM, Liu CY, Huang KH, Ko YS, Chung KF, Kuo HP. Increased circulating fibrocytes in asthma with chronic airflow obstruction. Am J Respir Crit Care Med. 2008;178:583-591.
34. Yang L, Scott PG, Giuffre J, Shankowsky HA, Ghahary A, Tredget EE. Peripheral blood fibrocytes from burn patients: identification and quantification of fibrocytes in adherent cells cultured from peripheral blood mononuclear cells. Lab Invest. 2002;82:1183-1192.
35. Chesney J, Metz C, Stavitsky AB, Bacher M, Bucala R. Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes. J Immunol. 1998;160:419-425.
36. Mehrad B, Burdick MD, Zisman DA, Keane MP, Belperio JA, Strieter RM. Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease. Biochem Biophys Res Commun. 2007;353:104-108.
37. Pilling D, Vakil V, Gomer RH. Improved serum-free culture conditions for the differentiation of human and murine fibrocytes. J Immunol Methods. 2009;351:62-70.